Abstract:Background: Programmed cell death protein 1 (PD1; also known as CD279) is an inhibitory receptor on T lymphocytes interacting with PD1-ligand 1 and PD1-ligand 2 in the synapse of T cells and antigen presenting cells (APC) resulting in the suppression of T cell activity. Systematic evolution of ligands by exponential enrichment (SELEX) is a method for generating aptamers which can bind specifically to the target of interest. PD-1 antagonistic aptamers could introduce an attractive alternative over the antibody-based treatments due to the distinguished advantages of aptamers including small size and efficient tissue penetration, low cost, lack of immunogenicity, and ease of manufacturing. Methods: Here, we developed single-stranded DNA aptamers which bind specifically to the human extracellular domain of PD-1. We performed hybrid SELEX, a combination of targeting of recombinant proteins and cell membrane expressed PD1 to select and identify specific aptamers and for the first time, homology of aptamer sequences selected from protein and cell SELEX pool have been evaluated in this study. Results: C42–aptamer, one of the selected aptamers, could specifically bind to human PD1 with dissociation constant in the nanomolar range. Although the developed aptamer inhibited binding of PD1 to PD-L1 but it was not able to restore the cell proliferation and cytokine production of the CD8+ CD279+ T cells. Conclusion: Further studies are required to assess the therapeutic potential of C42 aptamer and other aptamers developed in this study. The introduced PD1 specific aptamers can be used for specific detection of PD1 in diagnostic assay such as immunohistochemistry and targeted drug delivery to PD+ T cells.Using hybrid SELEX for generating ssDNA aptamer against PD1. (a) In the initial round of selection, ssDNA library was added to protein-loaded Ni-NTI magnetic beads, unbound aptamer was then eluted and PCR amplification performed. ssDNA was generated from PCR-amplified dsDNA and protein-free beads was used for counter selection. After 13 rounds, SELEX process was screened by the flow cytometry of beads. The selected pool of round 11 was transferred to the next phase (cell SELEX) and cloned for sequencing. (b) Stimulated Jurkat cells were used as PD1 positive cell and A2780 used as PD1 negative cell in the process of cell SELEX. Selected pool of round 1 and 2 was screened for the enrichment of aptamer by flow cytometry. Pool aptamers from the 1st round of cell SELEX were also selected for cloning and sequencing. (c) Aptamers with the ability to bind PD1 were selected for further analysis using blocking assay. PD-L1 with IgG fc-tag was added to PD1-expressing cells then binding of PD-L1 to PD1 was detected using FITC-conjugated antibodies against IgG fc-tag in either the presence or absence of aptamer.

The selection of a hydrophobic 7-phenylbutyl-7-deazaadenine-modified DNA aptamer with high binding affinity for the Heat Shock Protein 70

Rapid Identification Of Specific Dna Aptamers Precisely Targeting Cd33 Positive Leukemia Cells Through A Paired Cell-Based Approach

Design of A Flexible Cell-Based Assay for the Evaluation of Heat Shock Protein 70 Expression Modulators

In Silico Design and Validation of High-Affinity RNA Aptamers Targeting Epithelial Cellular Adhesion Molecule Dimers

High-affinity one-step aptamer selection using a non-fouling porous hydrogel

Discovery and Characterization of a Cryptic Secondary Binding Site in the Molecular Chaperone HSP70

Selection and Characterization of a DNA Aptamer Recognizing High Mobility Group Box 1 Protein (HMGB1) and Enhancing Its Pro-inflammatory Activity

An aptasensing platform for detection of heat shock protein 70 kDa (HSP70) using a modified gold electrode with lady fern-like gold (LFG) nanostructure

Identifying high-affinity aptamer ligands with defined cross-reactivity using high-throughput guided systematic evolution of ligands by exponential enrichment

A high-dimensional microfluidic approach for selection of aptamers with programmable binding affinities

Aptamers Can Discriminate Alkaline Proteins with High Specificity.

Selection of regioselective DNA aptamer for detection of homocysteine in nondeproteinized human plasma

High-throughput screen for Escherichia coli heat shock protein 70 (Hsp70/DnaK): ATPase assay in low volume by exploiting energy transfer

Development of DNA aptamers targeting B7H3 by hybrid-SELEX: an alternative to antibodies for immuno-assays

Molecular Crowding Evolution for Enabling Discovery of Enthalpy-Driven Aptamers for Robust Biomedical Applications

Revealing the molecular interactions of aptamers that specifically bind to the extracellular domain of HER2 cancer biomarker protein: An in silico assessment

[Screening and Structure Analysis of the Aptamers Against Human Recombinant S100A8 Protein].

Development and Evaluation of Novel Aptamers Specific for Human PD1 Using Hybrid Systematic Evolution of Ligands by Exponential Enrichment Approach

Selection and identification of a DNA aptamer targeted to Vibrio parahemolyticus.

Development of DNA aptamers specific for small therapeutic peptides using a modified SELEX method

Screening and characterization of aptamers for recombinant human programmed death-1 and recombinant extracellular domain of human programmed death ligand-1